What is BridgeBio Pharma, Inc.'s Shariah compliance score?

BridgeBio Pharma, Inc. (BBIO) has a Shariah compliance score of 60/100 (Grade: B, Acceptable) based on AAOIFI screening standards. Scores above 70 typically indicate strong compliance. The score factors in business activity screening and financial ratio analysis including debt levels, interest-bearing deposits, and prohibited income percentages. View the full breakdown at HalalScreener.app.

Does BridgeBio Pharma, Inc. pass AAOIFI screening?

BridgeBio Pharma, Inc. (BBIO) partially passes with caution AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (BBIO: 16.6%), (3) interest-bearing deposits below 30% (BBIO: 3.4%), and (4) prohibited income below 5% (BBIO: 4.6%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for BridgeBio Pharma, Inc. stock?

BridgeBio Pharma, Inc. (BBIO) has a non-permissible income ratio of 4.62%. Muslim investors should purify this percentage of any dividends received and capital gains realized from BBIO shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen BridgeBio Pharma, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for BridgeBio Pharma, Inc. (BBIO) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about BBIO's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

BBIO: Is BridgeBio Pharma, Inc. Halal?

BridgeBio Pharma, Inc.

NASDAQHealthcareUS

$63.88

-2.26%

Market Cap: 12.5B

Compliance Status

Doubtful

Screened on Jul 20, 2026 · AAOIFI Standard 21

Acceptable

60Score

Is BridgeBio Pharma, Inc. (BBIO) halal? Doubtful. Based on AAOIFI screening, BridgeBio Pharma, Inc. passes the business activity screen but has financial ratios approaching AAOIFI limits with a compliance score of 60/100 (Grade: B).

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Within the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

16.6% of 30.0% limit

What this means for you

You may own BBIO, with caution

Its numbers sit close to AAOIFI limits. Cautious investors may prefer alternatives or ask a scholar first.

Purify 4.6% of your income from BBIO

That is about $4.60 of every $100 you earn from it. Donate this share to charity.

Calculate my exact amount

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Sector: Healthcare · Industry: Biotechnology

Why This Stock Is Doubtful

Non-compliant income is 4.6% of revenue, only 0.4 points below the 5% limit

Stocks are marked Doubtful when financial ratios pass but approach AAOIFI thresholds. Consider consulting a qualified scholar for a definitive ruling.

Shariah Compliance Status

AAOIFI Standard 21Updated Jul 20, 2026

Compliance History

Doubtfulnow
since Jun 2026
Not Halal
until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: Q1 2026Data source: EDGAR

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track BBIO and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is BridgeBio Pharma, Inc. (BBIO) halal to invest in?

BridgeBio Pharma, Inc. (BBIO) is rated Doubtful under AAOIFI Standard 21. It passes the business activity screen but one or more financial ratios are approaching (though not yet exceeding) the AAOIFI thresholds (30% for debt and interest deposits, 5% for prohibited income). Consult a qualified Islamic finance scholar for a personal ruling.

Why did BridgeBio Pharma, Inc. get a B compliance rating?

BridgeBio Pharma, Inc. (BBIO) received a grade of B (Acceptable) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 16.6% (limit 30%); interest-bearing deposits of 3.4% (limit 30%); prohibited income of 4.62% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change BridgeBio Pharma, Inc.'s Shariah verdict?

BridgeBio Pharma, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is BridgeBio Pharma, Inc. re-screened for Shariah compliance?

BridgeBio Pharma, Inc. (BBIO) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jul 20, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.